Analgesic Effects of Antiosteoporotic Drugs.
10.4184/jkss.2017.24.1.59
- Author:
Dong Ki AHN
1
;
Won Shik SHIN
;
Go We KIM
Author Information
1. Seoul Sacred Heart General Hospital, Orthopedic Department, Korea. adk0208@hanmail.net
- Publication Type:Review
- Keywords:
Osteoporotic pain;
Analgesic effect;
Anti-osteoporotic drugs
- MeSH:
Anabolic Agents;
Analgesia;
Analgesics;
Back Pain;
Bone Density Conservation Agents;
Calcitonin;
Diphosphonates;
Korea;
Narcotics;
Osteoporosis;
Selective Estrogen Receptor Modulators;
Spine;
Teriparatide
- From:Journal of Korean Society of Spine Surgery
2017;24(1):59-64
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
STUDY DESIGN: Literature review. OBJECTIVES: To propose possible mechanisms of osteoporotic back pain and its management with antiosteoporotic drugs. SUMMARY OF LITERATURE REVIEW: No general conclusion has yet been reached regarding whether osteoporosis without fractures can cause pain. Instead, only treatments for back pain without osteoporotic spine fractures have been reviewed in the previous literature. Although key studies of antiosteoporotic drugs have not investigated their analgesic efficacy, plausible mechanisms have been suggested. MATERIALS AND METHODS: The analgesic effects of antiosteoporotic agents available in Korea were reviewed. RESULTS: Rather than the long-term use of conventional analgesics or narcotics, antiosteoporotic drugs would be more beneficial because they can enhance bone strength and have fewer side effects. Both anabolic and antiresorptive agents available in Korea have been proven to have an analgesic effect against osteoporotic back pain, with or without fractures. Anabolic agents depend on skeletal effects. Among antiresorptive agents, bisphosphonates have both skeletal and extraskeletal mechanisms for analgesia. Calcitonin and selective estrogen receptor modulators mostly depend on extraskeletal effects. The order of analgesic strength for osteoporotic back pain is teriparatide > bisphosphonate > calcitonin. This implies that the analgesic effect of antiosteoporotic drugs primarily depends on their skeletal effects rather than on their extraskeletal effects. Moreover, because non-fracture osteoporotic pain has been recognized only in the spine, where fractures can occur without a sensible injury, pain may arise from undiscovered spine fractures. CONCLUSIONS: Antiosteoporotic drugs ameliorate osteoporotic back pain. Their analgesic strength is proportional to their fracture prevention efficacy.
